<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522"><gtr:id>4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522</gtr:id><gtr:name>UNLISTED</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Genetics and Epidemiology</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522"><gtr:id>4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522</gtr:id><gtr:name>UNLISTED</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5305FC65-0A73-4B28-BAFD-B07BEFE8C82A"><gtr:id>5305FC65-0A73-4B28-BAFD-B07BEFE8C82A</gtr:id><gtr:firstName>Clare</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Turnbull</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700491"><gtr:id>8BC59397-CA7C-4B00-9417-DA2EEA2BCFBD</gtr:id><gtr:title>Clinical and Molecular Investigations of Familial Breast-Ovarian Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0700491</gtr:grantReference><gtr:abstractText>Breast and ovarian cancer can occur together in some families. Faults in two genes, BRCA1 and BRCA2, are known to increase the risks of breast and ovarian cancer resulting in families with both cancers (known as breast-ovarian cancer families). Individuals from families with BRCA1 or BRCA2 faults can undergo gene testing to see if they are at-risk of cancer. Individuals without the fault are reassured and those with the fault can have surveillance and/or preventative surgery to reduce their risk of cancer. However, the majority of breast-ovarian cancer families are not due to faults in BRCA1 or BRCA2 and there is currently little information available on how to best manage them. We have recruited 705 families with breast-ovarian cancer and I shall increase this to 1300 families. I shall investigate the contribution of BRCA1 and BRCA2 faults to these families and will look to see if newer breast cancer susceptibility genes, ATM, CHEK2, BRIP1 and PALB2 have a role in familial breast-ovarian cancer. By analysing the patterns of cancer clustering and gene faults in the families we will be able to clarify the cancer risks to unaffected relatives in breast-ovarian cancer families, which will allow us to better manage them in clinic.</gtr:abstractText><gtr:technicalSummary>AIMS
1. To investigate the contribution of breast cancer susceptibility genes to familial breast-ovarian cancer.
2. To improve risk estimation and management of breast-ovarian cancer families. 

BACKGROUND
Mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer but only account for a minority of breast cancer families. Further high penetrance predisposition genes have not been discovered and the residual susceptibility to breast cancer is believed to reside in multiple genes with smaller effects. The Breast Cancer Genetics Team at the ICR has led the way in identifying such genes and in recent years has demonstrated that inactivating mutations in CHEK2, ATM, BRIP1 and PALB2 double the risk of breast cancer. Families that include individuals with breast cancer and individuals with ovarian cancer (?breast-ovarian cancer families?) have been largely attributed to BRCA1 and BRCA2. However, BRCA1/2 mutations are not found in the majority of the smaller (&amp;lt;5 cases) breast-ovarian cancer clusters that are typically seen in the clinic. Robust cancer risks and optimal management for such families remain unclear. Given the close functional interaction between the recently identified lower penetrance genes and BRCA1/BRCA2, it is plausible that they are likewise contributing to familial breast-ovarian cancer and we have preliminary data to support this. To clarify genetic susceptibility underlying familial breast-ovarian cancer I have the following objectives: 

OBJECTIVES
1: To construct a comprehensive resource of data and biological samples on 1300 breast-ovarian cancer families
2: To investigate the frequency of mutations in breast cancer susceptibility genes in 1300 breast-ovarian families
3: To investigate the phenotypes and risks associated with mutations in CHEK2, ATM, BRIP1 and PALB2
4: To improve clinical management of familial breast-ovarian cancer

METHODS
Using 705 existing breast-ovarian cancer families and 600 additional familthat I shall recruit, I shall generate a series of ~300 breast-ovarian cancer families with BRCA1/2 mutations and ~1000 families in which mutations have been excluded. I shall screen CHEK2, ATM, BRIP1 and PALB2 in index cases from all BRCA1/2 negative families using a combination of techniques. 
In families with mutations I shall screen additional family members, review the clinical and pathological phenotype and estimate the cancer risks. I shall also undertake analyses of the full series to examine the contribution of known genes and to model the likely underlying susceptibility of the residual families. I shall use these combined data to inform clinical management of breast-ovarian cancer families.</gtr:technicalSummary><gtr:fund><gtr:end>2011-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>230345</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Institute for Cancer Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Branch</gtr:department><gtr:description>TP53 binding</gtr:description><gtr:id>600D1DD6-326A-4FF7-9812-43A1298D09D5</gtr:id><gtr:impact>ongoing analyses</gtr:impact><gtr:outcomeId>AdQS1ozvLVu-1</gtr:outcomeId><gtr:partnerContribution>Functional analyses of TP53 binding sites</gtr:partnerContribution><gtr:piContribution>Analysis of genetic associations for testicular cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Perelman School of Medicine</gtr:department><gtr:description>TeCAC</gtr:description><gtr:id>66616945-513C-4329-8E88-96A18D285D3B</gtr:id><gtr:impact>2 publications</gtr:impact><gtr:outcomeId>qMyRgfzxh2G-2</gtr:outcomeId><gtr:partnerContribution>Collaborative analysis of GWAS data for testicular cancer</gtr:partnerContribution><gtr:piContribution>Collaborative analysis of GWAS data for testicular cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southern California</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Preventive Medicine</gtr:department><gtr:description>TeCAC</gtr:description><gtr:id>BCC8891E-C805-4296-B0FB-739CB062F122</gtr:id><gtr:impact>2 publications</gtr:impact><gtr:outcomeId>qMyRgfzxh2G-1</gtr:outcomeId><gtr:partnerContribution>Collaborative analysis of GWAS data for testicular cancer</gtr:partnerContribution><gtr:piContribution>Collaborative analysis of GWAS data for testicular cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk at House of Commons</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>07F45A5F-577A-4780-AAAD-55ED3F452AA5</gtr:id><gtr:impact>Talk on Precision Medicine at the House of Commons</gtr:impact><gtr:outcomeId>56d45d6f342cb2.67844416</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Magazine interview Men's Health 2015</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>287B780A-FC02-4221-BA34-0493DA00AC5A</gtr:id><gtr:impact>INterview about testicular cancer and mens health</gtr:impact><gtr:outcomeId>56d45ca4aacfc1.65413563</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.menshealth.co.uk/healthy/beat-testicular-cancer</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Doctors net interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>30FF35E1-65E4-4262-8778-2D1410958714</gtr:id><gtr:impact>5 minute interview at NCRI conference featured on Doctors.net.uk website, aimed at broad medical audience, Topic: a more mainstreamed approach to genetic testing

Site accessed by &amp;gt;200,000 doctors</gtr:impact><gtr:outcomeId>WvGEQUVpnTJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.doctors.net.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Film for The Science Museum</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23790168-D006-4DF2-84C4-68D5688E0371</gtr:id><gtr:impact>Film on Big Data to be screened at the Science Museum in mid 2016</gtr:impact><gtr:outcomeId>56d45cf52c2978.38529883</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TED-style talk at Adobe Technology Summit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>77F92F18-E5DA-424A-A438-C66A3ED27F50</gtr:id><gtr:impact>o TED-style talk for Adobe.Technology Summit at Excel 2015: &amp;quot;Mother Nature's Big Data&amp;quot;</gtr:impact><gtr:outcomeId>56d45c35df5262.49741771</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://2015.summit.adobe.com/emea/speakers/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MCG press conference</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>38013DA0-A5A6-48FB-AA73-C34741A4D1A2</gtr:id><gtr:impact>Press briefing as one of panel of 4 expert speakers via Wellcome Trust Media Center regarding extension of genetic testing for breast cancer predisposition

Widespread coverage eg BBC 6 o'clock News</gtr:impact><gtr:outcomeId>JUaHE7oScGU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Movember launch</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>48B8001E-D64C-47C3-BE88-F20AA98460B2</gtr:id><gtr:impact>Publicizing public health message about testicular cancer and research into testicular cancer to audience of 900 men.

Additional requests to talk to audiences. Article in the Metro</gtr:impact><gtr:outcomeId>r4yYFE7xbVX</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Podcast recording</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5A7020E-1C7C-429A-8990-F740430CFC3A</gtr:id><gtr:impact>15 minute podcase recording for Movember radio on Men's Health and testicular cancer</gtr:impact><gtr:outcomeId>56d45bd4cc4694.99282469</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.podcastchart.com/podcasts/movember-radio/episodes/ep-12-clare-turnbull</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab Tour</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8D7CD3F0-6CA1-4671-8594-3A523763C250</gtr:id><gtr:impact>Lab tour and science afternoon for 10 Movember fundraisers to engage them in the science behind the fundraising

Additional requests for me to talk to lay audiences</gtr:impact><gtr:outcomeId>bN8acdhBxY6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://instituteofcancerresearch.wordpress.com/tag/movember/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Movember Film</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C3E5D00C-0EDC-46A6-A94B-789809DBDA75</gtr:id><gtr:impact>Worked with Movember to develop 2 minute film to go go onto their website and designed to go viral. Film about testicular cancer and research into the disease. Final film featured Ray Winstone and Jimmy White

&amp;gt;20,000 hits in its first week</gtr:impact><gtr:outcomeId>MYFADR94tke</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=Yvc2UjkSddA</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>764646</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A696F8C3-6EBE-4D04-BF52-6E8DAD7B39DE</gtr:id><gtr:outcomeId>YEYLGnXEP5m0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Based on these principles, we have built an initial prototype of this system, which we entitled CaVaDa (Cancer Variant Datasystem: http://CaVaDa.dynalias.org/CaVaDa/.)
This prototype is, in brief, a mySequel database of 74 tables accessed via a Shiny web interface (code available in a wiki at http://CaVaDa.dynalias.org/mediawiki/index.php/Main_Page). The database contains &amp;gt;1.2 million variants (ie all possible base substitutions in 106 cancer susceptibility genes) for all of which there are generic (ie non-gene specific) variant-level inputs such as in-silico predictions (eg AlignGVGD, SIFT, MAPP, Polyphen, CaDD, SusPECT, MaxEnt) and population data (1000GP, EVS). For BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2, we have also integrated multiple expert-selected gene-level gene-specific inputs (eg LOVDs and selected large scale functional and genetic epidemiologic analyses). In consultation with experts in the field, Turnbull has developed gene-specific classification rules and had programmed computational gene-specific decision trees, applied to data inputs to produce systematic and 'automated classifications' for all variants in these genes (see Appendix 1). 
The CaVaDa web interface offers an 'Explore' function (for looking up a single variant) and a 'batch' function (for import of .txt or .csv file of vars; flexible to varying nomenclature). CaVaDa' s data and classifications can be outputted either via a PDF (for a single variant; see Appendix 2) or an annotated .xls (for a set of variants). The system also allows for input of notes and 'curated classifications' which a number of current users have submitted. Any PMIDs included in text are automatically hyper-linked out.
This system is was developed in an heuristic, iterative fashion as a proof of concept over 7 months by Turnbull (clinical academic; 0.1 WTE) and Sultana (software engineer, 0.8 WTE). It is currently informally hosted on a domestic server but is in use by a number of research laboratories (Gonzalez de Castro laboratory (CMP ICR/RMH), Swanton laboratory (Crick), Eeles laboratory (ICR), Sternburg laboratory (Imperial)) as well as numerous clinicians and clinical genetics departments.</gtr:description><gtr:id>6372141F-D50F-487A-81DE-DB24DD528459</gtr:id><gtr:impact>Supporting molecular cancer research from a number of notable PIs</gtr:impact><gtr:outcomeId>56d45fc414f9a1.84814770</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CaVaDa Cancer Variant database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://cavada.dynalias.org/cavada/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>70E66CCD-5E0D-43DB-90A2-E9F2D58B3BB7</gtr:id><gtr:title>DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9f5b5130fc1063af766d26cb9cfd5a5"><gtr:id>d9f5b5130fc1063af766d26cb9cfd5a5</gtr:id><gtr:otherNames>Slade I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>TCEAtJMXwQk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE5BD6A2-B2D9-4870-B869-B3EF3828722A</gtr:id><gtr:title>A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daf6050b3ee71ce4b7cccb66482ed04c"><gtr:id>daf6050b3ee71ce4b7cccb66482ed04c</gtr:id><gtr:otherNames>Siddiq A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_15322_22_22976474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2173C0A-586C-4818-819C-677205F3219A</gtr:id><gtr:title>MicroRNA related polymorphisms and breast cancer risk.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f866ece9ee13c82de8b8a205ee4b33b2"><gtr:id>f866ece9ee13c82de8b8a205ee4b33b2</gtr:id><gtr:otherNames>Khan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d4589dbf64d1.46857307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B860738-DEB1-4FFF-A29F-B81805DD6F47</gtr:id><gtr:title>Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/993d22cedb6d8f5effbd6baf47d7b27c"><gtr:id>993d22cedb6d8f5effbd6baf47d7b27c</gtr:id><gtr:otherNames>Snape K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>pm_15322_22_22527104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BAFFCC9-907D-4485-A71F-00E840415476</gtr:id><gtr:title>Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour.</gtr:title><gtr:parentPublicationTitle>International journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0105-6263</gtr:issn><gtr:outcomeId>LPjTaZwfpFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEFA2793-1050-43BD-AD0E-680C0899A164</gtr:id><gtr:title>Prediction of breast cancer risk based on profiling with common genetic variants.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bf1c628f1c68d5d7df904021048cfa7"><gtr:id>3bf1c628f1c68d5d7df904021048cfa7</gtr:id><gtr:otherNames>Mavaddat N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>56d4589c5fc5b5.78358348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>766D0FD4-A818-4FB2-B30C-B873D6A3B05D</gtr:id><gtr:title>Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>GXMPin7dmRx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C556E70C-41F7-4479-8B1E-FF92AB622E2D</gtr:id><gtr:title>A genome-wide association study of testicular germ cell tumor.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a53fbf0a19e7eea118d04bb9f3f13c1c"><gtr:id>a53fbf0a19e7eea118d04bb9f3f13c1c</gtr:id><gtr:otherNames>Rapley EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>Piv8gkAR8fW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ADD3F72-ED46-4A63-90FE-91EB63A73AB7</gtr:id><gtr:title>Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project.</gtr:title><gtr:parentPublicationTitle>Genetics in medicine : official journal of the American College of Medical Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8888fe632202324e289dff1e8c0394"><gtr:id>1b8888fe632202324e289dff1e8c0394</gtr:id><gtr:otherNames>Robbe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1098-3600</gtr:issn><gtr:outcomeId>5a982d27e64b52.45505390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4433225B-9385-4E67-A1AB-3D63789AA5FC</gtr:id><gtr:title>Testicular cancer in 2017: Sequencing advances understanding.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>5a982d287618b2.25314502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB4CE000-116C-4024-9C9D-7CB7B88C74D4</gtr:id><gtr:title>Mendelian randomisation study of the relationship between vitamin D and risk of glioma.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b519a52f79440e83121055aa73608c08"><gtr:id>b519a52f79440e83121055aa73608c08</gtr:id><gtr:otherNames>Takahashi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a982d27b4ff38.16443012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B74F343-D88E-4BD3-A5AD-C37D997D0C6A</gtr:id><gtr:title>Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d00dba11f2f48cb58cfda1e008a23353"><gtr:id>d00dba11f2f48cb58cfda1e008a23353</gtr:id><gtr:otherNames>Zeng C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>58c14e67448476.76116874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA61114D-3A0B-4D7D-8C7D-B665520FB585</gtr:id><gtr:title>Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a32e5e38a8b83514d902fbe4626b80ee"><gtr:id>a32e5e38a8b83514d902fbe4626b80ee</gtr:id><gtr:otherNames>Wellcome Trust Case Control Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>EE27mg4NTuh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33862462-4C12-478D-9207-889CA10B61CC</gtr:id><gtr:title>Gene-gene interactions in breast cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>REaJzmUhF9Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1B90F84-5DDE-408B-903E-5A5168456392</gtr:id><gtr:title>Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e334542d213e03328c3152534f9303e8"><gtr:id>e334542d213e03328c3152534f9303e8</gtr:id><gtr:otherNames>Milne RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>MQ6ErcnpuiD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>987A24ED-B0F2-483E-9CEE-0FF5CCBF75FA</gtr:id><gtr:title>Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7df3307e11c9bb132b88045342e68068"><gtr:id>7df3307e11c9bb132b88045342e68068</gtr:id><gtr:otherNames>Ruark E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_15322_22_23242139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85C2CE56-9D90-425F-B12B-D07B54DEC1FA</gtr:id><gtr:title>Mammographic breast density and breast cancer: evidence of a shared genetic basis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5095d1dd5cffc083f6e88a4d5b31ede"><gtr:id>f5095d1dd5cffc083f6e88a4d5b31ede</gtr:id><gtr:otherNames>Varghese JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_15322_22_22266113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FC1106F-44A6-4CB7-85E6-4696C420D64F</gtr:id><gtr:title>Mendelian randomisation analysis provides no evidence for a relationship between adult height and testicular cancer risk.</gtr:title><gtr:parentPublicationTitle>Andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/500eb111ee39c0d64026f276b07d6dae"><gtr:id>500eb111ee39c0d64026f276b07d6dae</gtr:id><gtr:otherNames>Levy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-2919</gtr:issn><gtr:outcomeId>5a982d28a2a240.85710516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>150B300A-E495-4DC0-AFD3-1D0FBF4F9A48</gtr:id><gtr:title>Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb7f91f987c102cf01d75f78ca355260"><gtr:id>bb7f91f987c102cf01d75f78ca355260</gtr:id><gtr:otherNames>Figueroa JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>BsPN38AST1F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>671BA56C-7767-4FBA-8B27-45098E1E9495</gtr:id><gtr:title>Genome-wide association study identifies five new breast cancer susceptibility loci.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>eiLxnBA4Y1G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96655F4F-CF9A-48B3-9BDE-6047C9654ADC</gtr:id><gtr:title>Germline mutations in RAD51D confer susceptibility to ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e36ab8ab4113e4d22efa24b7e54ff6ee"><gtr:id>e36ab8ab4113e4d22efa24b7e54ff6ee</gtr:id><gtr:otherNames>Loveday C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>MY5QX1GULdM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D1CD854-4570-431A-9E48-5C4A7EF94055</gtr:id><gtr:title>BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebd09e24277ca660cd7211f4649b8165"><gtr:id>ebd09e24277ca660cd7211f4649b8165</gtr:id><gtr:otherNames>Robertson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_15322_22_22333603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2749C79-BB0F-43BE-BEC2-94C6C068D204</gtr:id><gtr:title>Genome-wide association analysis identifies three new breast cancer susceptibility loci.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71e2ebd1f2b2b3fb1e5851e7c43fcdba"><gtr:id>71e2ebd1f2b2b3fb1e5851e7c43fcdba</gtr:id><gtr:otherNames>Ghoussaini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_15322_22_22267197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D291ABCC-4A21-4917-AEC8-024094534FC7</gtr:id><gtr:title>Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35a76377e33985467fab8f79e5b3ec98"><gtr:id>35a76377e33985467fab8f79e5b3ec98</gtr:id><gtr:otherNames>Fehringer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58c14e66996e30.77927581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B7CC4ED-97CC-45D0-9819-B63487B886A8</gtr:id><gtr:title>Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e334542d213e03328c3152534f9303e8"><gtr:id>e334542d213e03328c3152534f9303e8</gtr:id><gtr:otherNames>Milne RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>FgiXc19aupZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E64B0DD4-F53D-4248-9F52-24CF3356C7FE</gtr:id><gtr:title>Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ea13110c8c27f52784ab3deca8cab1a"><gtr:id>4ea13110c8c27f52784ab3deca8cab1a</gtr:id><gtr:otherNames>Manchanda R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>5a982d28269728.72673943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35EDC9D1-C3C9-4603-A486-BD2F7341500E</gtr:id><gtr:title>Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b10a9b045d259c5e707d9097184968a"><gtr:id>2b10a9b045d259c5e707d9097184968a</gtr:id><gtr:otherNames>Michailidou K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56d4589cc47b94.88521522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>241AC99E-31FC-46E7-985B-D7113EED4799</gtr:id><gtr:title>Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.</gtr:title><gtr:parentPublicationTitle>American journal of obstetrics and gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2e25a4fa01d4e26232388505f7d2e49"><gtr:id>c2e25a4fa01d4e26232388505f7d2e49</gtr:id><gtr:otherNames>Patel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9378</gtr:issn><gtr:outcomeId>5a982d28520938.12341996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4FF1272-C277-429E-92F5-86F1B06204ED</gtr:id><gtr:title>Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e19ae5083ed5aaa39efec872cb82c5"><gtr:id>68e19ae5083ed5aaa39efec872cb82c5</gtr:id><gtr:otherNames>Litchfield K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a982d295636c5.52013060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DE24B67-ABEA-4F18-AF0E-B8E5E1B0B5BE</gtr:id><gtr:title>Mutation and association analysis of GEN1 in breast cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>CswzaKKWj9X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE4EEC6F-4B2E-45A9-B9D8-B763472A9C8A</gtr:id><gtr:title>Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/904f884f2cedac3bc8311c15aeb35f7b"><gtr:id>904f884f2cedac3bc8311c15aeb35f7b</gtr:id><gtr:otherNames>Wang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a982d29139133.00789393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B64ED8C1-0B5A-4404-BA48-7BB42CE84D26</gtr:id><gtr:title>Development of cancer genetic services in the UK: A national consultation.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9f5b5130fc1063af766d26cb9cfd5a5"><gtr:id>d9f5b5130fc1063af766d26cb9cfd5a5</gtr:id><gtr:otherNames>Slade I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>56d4589d1cf732.27985791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F612B755-F81F-4E82-B44D-9B1356A605C1</gtr:id><gtr:title>Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.</gtr:title><gtr:parentPublicationTitle>JAMA oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1282d5d2fc80d7756326a54578cb41f8"><gtr:id>1282d5d2fc80d7756326a54578cb41f8</gtr:id><gtr:otherNames>Telomeres Mendelian Randomization Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2374-2437</gtr:issn><gtr:outcomeId>5a982d29898431.41548905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F0F13A9-F8E5-45AC-934F-8DB0804C75C0</gtr:id><gtr:title>Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/761412bbacc279937be59e324cc79b0d"><gtr:id>761412bbacc279937be59e324cc79b0d</gtr:id><gtr:otherNames>Couch FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c14e67b88fa8.96475700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF94BCE2-3C88-4655-A1FC-BDBBC98A7A7A</gtr:id><gtr:title>Genetic predisposition to breast cancer: past, present, and future.</gtr:title><gtr:parentPublicationTitle>Annual review of genomics and human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1527-8204</gtr:issn><gtr:outcomeId>YnjNzYTdJU4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB3035B5-64F3-4694-AA52-239CAD2DB620</gtr:id><gtr:title>Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e19ae5083ed5aaa39efec872cb82c5"><gtr:id>68e19ae5083ed5aaa39efec872cb82c5</gtr:id><gtr:otherNames>Litchfield K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5a982d2787f4f0.03799891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F6B4649-54BC-48AB-B354-AD95EB97E053</gtr:id><gtr:title>Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fed9769918b6645f91704266283972c"><gtr:id>5fed9769918b6645f91704266283972c</gtr:id><gtr:otherNames>Kirchhoff T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15322_22_22768030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1681090B-F752-491E-A6B6-3EAB8F342ACF</gtr:id><gtr:title>Germline RAD51C mutations confer susceptibility to ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e36ab8ab4113e4d22efa24b7e54ff6ee"><gtr:id>e36ab8ab4113e4d22efa24b7e54ff6ee</gtr:id><gtr:otherNames>Loveday C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_15322_22_22538716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55925DDB-F5BB-40E5-AD28-7858120D928B</gtr:id><gtr:title>Introducing Whole Genome Sequencing into routine cancer care: The Genomics England 100,000 Genomes project.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2f2bef0d944e21b6e82d6c29b829e42"><gtr:id>c2f2bef0d944e21b6e82d6c29b829e42</gtr:id><gtr:otherNames>Turnbull C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>5a982d275b0897.51313135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97AE9547-D6C5-489D-8674-069946A5A85B</gtr:id><gtr:title>Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.</gtr:title><gtr:parentPublicationTitle>American journal of obstetrics and gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ea13110c8c27f52784ab3deca8cab1a"><gtr:id>4ea13110c8c27f52784ab3deca8cab1a</gtr:id><gtr:otherNames>Manchanda R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9378</gtr:issn><gtr:outcomeId>5a982d28d93419.51841364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9BD6F7C-59FD-4C7C-8C7B-691BCA97B333</gtr:id><gtr:title>Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90fb521fb4609dc795b90be3158eb5e1"><gtr:id>90fb521fb4609dc795b90be3158eb5e1</gtr:id><gtr:otherNames>Song H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>e4RqaiGuFbA</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700491</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>